- Home
- HERZ vs IXHL Comparison
HERZ vs IXHL Comparison
Compare HERZ & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HERZ | IXHL |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 49.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HERZ | IXHL |
|---|---|---|
| Price | $2.54 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 24.8M |
| Earning Date | N/A | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $0.08 |
| 52 Week High | N/A | $2.25 |
Technical Indicators
Market Signals| Indicator | HERZ | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 57.22 |
| Support Level | $2.44 | $0.38 |
| Resistance Level | $2.64 | $0.50 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 50.00 | 63.35 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.